



Article

Descriptive Observational Study of Tdap Vaccination Adhesion in Pregnant Women in the Florentine Area (Tuscany, Italy) in 2019 and 2020

Benedetta Bonito ¹, Daniela Balzi ², Sara Boccalini ¹, Paolo Bonanni ¹, Giovanna Mereu ², Maria Grazia Santini ² and Angela Bechini ^{1,*}

- Department of Health Sciences, University of Florence, 50134 Florence, Italy; benedetta.bonito@unifi.it (B.B.); sara.boccalini@unifi.it (S.B.); paolo.bonanni@unifi.it (P.B.)
- ² AUSL Toscana Centro, 50122 Florence, Italy; daniela.balzi@uslcentro.toscana.it (D.B.); giovanna.mereu@uslcentro.toscana.it (G.M.); mariagrazia.santini@uslcentro.toscana.it (M.G.S.)
- * Correspondence: angela.bechini@unifi.it; Tel.: +39-055-2751-081

Abstract: Background: Tdap (Tetanus-Diphtheria-acellular Pertussis) vaccination is nowadays a worldwide-recommended practice to immunize pregnant women. The vaccine administration at the third trimester of pregnancy (as recommended by the WHO) would ensure antibody protection to both the mother and the newborn and has contributed to the significant drop of pertussis cases in infants. The aim of this observational study was to describe for the first time the socio-demographic characteristics and determinants of Tdap vaccination adhesion of pregnant women in the Florentine area. Methods: Information about parents' vaccination status, their citizenship, employment type and mothers' previous pregnancies and/or abortions were collected at the time of birth through the assistance birth certificates (CedAP) both for the years 2019 and 2020. This archive and the regional SISPC (Collective Prevention Healthcare Information System) linked using an anonymous unique personal identifier to retrieve the mother's vaccination status. Results: We found an overall Tdap vaccination adhesion of 43% in 2019 and 47.3% in 2020. Several socio-demographic parameters would determine an increased vaccination adhesion, including parents' geographical origin, mothers' age and educational background, as well as the number of previous deliveries, abortions or voluntary termination of pregnancy. Conclusions: Since not much data are available on this topic in Italy, this study may constitute the baseline information for Tdap vaccination adhesion in pregnant women in the Florentine area (Italy). Thus, future successful vaccination strategies may be designed accordingly.

Keywords: COVID-19; pandemic; pregnancy; newborn; pertussis; vaccination; vaccination coverage; Florence; Italy

Citation: Bonito, B.; Balzi, D.; Boccalini, S.; Bonanni, P.; Mereu, G.; Santini, M.G.; Bechini, A. Descriptive Observational Study of Tdap Vaccination Adhesion in Pregnant Women in the Florentine Area (Tuscany, Italy) in 2019 and 2020. *Vaccines* 2021, 9, 955. https://doi.org/10.3390/ vaccines9090955

Academic Editors: Cristina Genovese, Squeri Raffaele, Claudio Costantino and Anna Odone

Received: 8 July 2021 Accepted: 24 August 2021 Published: 26 August 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Pregnancy represents one of the most important, crucial hallmarks in the life of a woman, and it may represent a time during which concerns and fears about the safety of vaccines may arise. As a matter of fact, immunization of pregnant women is now a world-wide recommended practice with a double positive effect. First, vaccination directly protects women against infectious diseases particularly dangerous in pregnancy (e.g., influenza); secondly, it also protects the newborns against diseases, such as tetanus and pertussis, until they develop a protecting level of antibodies [1,2]. In particular, pertussis (whooping cough) is a respiratory tract infectious disease caused by *Bordetella pertussis*. It is mostly asymptomatic or mildly symptomatic in older previously vaccinated subjects; on the contrary, it can be particularly severe in infants under 6 months of age, who are too

Vaccines **2021**, 9, 955

young to have received their primary dose of TDaP (Tetanus-Diphtheria-acellular Pertussis) vaccine and have the highest hospitalization and complication rates [3]. The disease incubation period is typically 9–10 days (range 6–20 days), and the classic clinical presentation in children is paroxysms of coughing, ending with the characteristic whoop and emesis (vomiting). The prognosis can be particularly severe in the first and second year of life, when incidence, as well as hospitalizations and case fatality rates (CFRs), are particularly high (CFRs: 0.2% and 4% in developed and developing countries, respectively) [4]. Deaths primarily occur for pulmonary complications.

The practice to vaccinate pregnant women started back between the 17th and 18th centuries in Asia and in Africa by inoculating smallpox to prevent the infection; since then, this practice was extended to Europe and America [5]. In the 1930s and 1940s, clinical trials on the first whole-cell pertussis vaccine in pregnancy demonstrated safety for the newborn and the potential to transfer protective levels of antibodies to the neonate, reporting no reactogenicity [6]. Pertussis is a worldwide endemic/epidemic infectious disease, reporting outbreaks usually every 2-5 years with a spring-summer seasonality [4]. In 2018, infants <1-year-old were the most affected age group by pertussis in Europe (except for Estonia and Norway), and three deaths were reported. The highest rates of pertussis in infants were reported in Austria (180.4 cases/100 000), followed by Iceland (146.6), Slovenia (123.6) and Denmark (121.5). Infants represented 6% of all cases reported; among those in which the month of age was known (87%), 65% were under six months old, and 45% were under three months old [3]. Moreover, Germany, the Netherlands, Norway, Spain and the United Kingdom altogether accounted for 72% of all notified cases in all age groups. In Italy, it has been reported a rising trend of pertussis hospitalizations in the period 2002–2016, and infants <1-year-old showed the highest percentage (63.4%) and average hospitalization rates (74.6/100 000) [7]. During the period 2010–2019, pertussis vaccination coverage (VC) rates in the Tuscany region were reported as > 95% (except for the year 2016); nevertheless, 38 cases of pertussis were notified in Tuscany in 2019, and 11 of these were hospitalized [8]. Importantly, it is known that mothers are the main source of infection for their babies within the households (39%), then fathers (16%) and grandparents (5%) [9]. It is, therefore, extremely important to immunize family members and careers too (cocoon strategy) in order to protect the unvaccinated newborns. According to this evidence, it is primarily critical to vaccinate pregnant women against diphtheria-tetanus-pertussis (Tdap), and hence, the Italian National Immunization Plan 2017-2019 (NIP) recommends giving the Tdap vaccination at the 28th week of pregnancy at each pregnancy, regardless of previous Tdap doses received [10]. Moreover, the Italian Ministry of Health endorsed two documents (in 2018 and in 2019), including recommendations on vaccinations for pregnant women [11,12]. Thus, based on international [13], national [11,12] and regional guidelines [14], the Local Health Unit Toscana Centro (LHU-TC) actively promoted Tdap vaccination in pregnant women, starting from the training of all the health professionals involved.

The aim of this observational study was to describe the socio-demographic characteristics and determinants of Tdap vaccination adhesion of pregnant women in the LHU-TC during the year 2019 and compare the vaccination adhesion to the year 2020.

2. Materials and Methods

The Tdap promotion vaccination guidelines in the LHU-TC were directed to: gynecologists and pediatricians (hospital and private practice), GPs, hygienists, public health professionals, healthcare assistants and medical doctors working in the vaccination centers. Particular attention was given to the midwives' category, which was trained by the Public Health Unit professionals. An informative vaccination booklet to be given to the women was also distributed to all the specialists working in the Healthcare Centers of the LHU-TC and to the GPs. In order to consistently promote vaccinations to pregnant women, all the professionals mentioned followed a common procedure and provided all

Vaccines 2021, 9, 955 3 of 10

the information at the delivery of the pregnancy booklet (which includes all the recommendations about Tdap vaccination) [15], at the pre-natal screening visits and during the routine mothers' visits (including the post-partum period). Pregnant women could receive the vaccination at the vaccination centers (even with no booked appointment), at their GP's, at the time of birth and even at the post-partum check, although at this time, vaccine efficacy may be reduced. For the purpose of this study, information about the parents' vaccination status, mother's age and geographical area of residence in the LHU-TC, their citizenship, employment type and the mothers' previous pregnancies and/or abortions were collected at birth time through the assistance birth certificates (CeDAP). This archive and the regional SISPC (Collective Prevention Healthcare Information System) (Consortium Metis, Tuscany, Italy) were linked using an anonymous unique personal identifier to retrieve mother's vaccination status.

Data were collected during the years 2019 and 2020, before and during the COVID-19 pandemic emergency. The description of the socio-demographic characteristics of the pregnant women resident in the LHU-TC was referred to the year 2019 database. The geographical area of origin was reported divided by the Ex LHU of residence: Pistoia, Prato, Florence, Empoli. The population enrolled in the year 2020 in the same geographical area accounted for 9652 subjects and presented comparable socio-demographic characteristics to those enrolled the year before. Tdap vaccination adhesion in pregnant women was retrieved for both 2019 and 2020 years.

Statistical significance was assessed with the chi-squared (χ^2) test, which was used to compare relative frequencies (assuming a *p*-value < 0.05 as statistically significant).

3. Results

Our sample population for the year 2019 included 10,063 women (*N*) resident in the LHU-TC. The social and demographic characteristics of the participants are shown in Table 1.

Table 1. Socio-demographic characteristics of the sample population enrolled in 2019. Frequency (%) = n/N.

Total Number (N) =	10,063				
Socio-Demographic Characteristics	n	n %			
Ex LHU of residence					
Pistoia	175	8	17.5		
Prato	163	1631 16.2		.2	
Florence	513	0	51.0		
Empoli	154	1544 15.3		5.3	
Age					
18–24	762	2	7.	1	
25–29	196	9	18	5.8	
30–34	340	7	35	35.2	
35–39	287	4	28	28.3	
40–44	934	4	9.	9.4	
45–49	103	3	1		
50–54	13	13		0.1	
Citizenship	Mothers	Fathers	Mothers	Mothers Fathers	
Italy	7034	5288	69.9	52.5	
Albany	619	519	6.2	5.2	
Romania	354	194	3.5	1.9	
China	559	470	5.6	4.7	
Morocco	259	207	2.6	2.1	
Peru	141	53	1.4	0.5	
Nigeria	85	62	0.8	0.6	
Senegal	88	69	0.9	0.7	

Vaccines **2021**, 9, 955 4 of 10

Otl	024	400	0.2	1.0
Other	924	489	9.2	4.9
N.D.	-	2712	-	27.0
Mothers' marital status				
Married	466			5.4
Unmarried	417			.5
Separated	65			.6
Divorced	69		0	
Widowed	4		0.0	
N.D.	108).7
Educational level	Mothers	Fathers	Mothers	Fathers
None	128	134	1.3	1.3
Middle school	2180	2535	21.7	25.2
High school	3885	3171	38.6	31.5
Bachelor's degree	1968	288	19.5	2.9
Master's degree	1166	1130	11.6	11.2
N.D.	737	2805	7.3	27.9
Occupational status				
Employed	6635		65.6	
Unemployed	1201		12.0	
Looking for first job	34		0.3	
Housewife	1513		15.3	
Student	59		0.6	
Other	604		6.0	
N.D.	17		0.2	
Previous conceptions			0.2	
Yes	609)1	60).5
No. previous deliveries	007	· 1	- 00	7.5
0	451	2	4/	I.9
	342			ł.0
1				
	130 500			3.0
3				.0
4	193			.9
5	66		0	
≥6	55)	0	.5
No. previous abortions				
0	786		78	
1	167			5.7
2	380			.8
3	96			.0
≥6	38			.4
N.D.	12	<u>-</u>	0	.1
No. previous VTP (voluntary termination of pregnancy)				
0	903			9.8
1	81	6		.1
2	15	4	1	.5
≥3	42	<u>!</u>	0	.4
N.D.	14		0	.1
Medically assisted				
Procreation				
Yes	50	6	5	.0
No. visits during pregnancy				
0	6		0	.1
1	134	4	1	.4
2	120			.2
3	32			.2

Vaccines **2021**, 9, 955 5 of 10

4	616	6.1
5	1609	16.0
6	1788	17.8
7	1556	15.5
8	1811	18.0
9	693	6.9
10	700	7.0
11	189	1.9
12	199	2.0
≥13	285	2.8
N.D.	32	0.3
		· ·

3.1. Tdap Vaccination Adhesion by Geographical Area of Residence, Age Group and Parents' Citizenship

Overall, the percentage of Tdap vaccinated women in our sample population in 2019 was 43.0% (4328/10063). Women resident in Prato showed the highest vaccination percentage (50.8%), followed by those resident in Pistoia (44.5%), Florence (42.9%) and Empoli (33.4%) (p < 0.05). Figure 1 shows the distribution of Tdap vaccinated women according to their age group. The most vaccinated were women belonging to the 35–39 age group (48%, 1380/2874), whereas the least were in the 18–24 age group (22.7%, 173/762) and in the 50–54 (30.8%, 4/13) (Figure 1). The chi-squared test reported to be statistically significant (p < 0.05).




Figure 1. The percentage distribution of Tdap vaccinated women in 2019 according to the age group. The dashed line indicates the average percentage adhesion: 43.0%.

Table 2 summarizes the Tdap vaccination status of the pregnant women by mother's and father's citizenship. Italian pregnant women (who are also the most represented in our sample) showed the highest vaccination rates: 51.1% among Italian mothers (3592/7034) and 49.4% among those having Italian partners (2611/5288). Moroccan, Senegalese and Nigerian mothers were those with the lowest Tdap vaccination adhesion: 10.4% for Morocco and 14% for pregnant women having Moroccan partners; 13.5% for mothers of Senegalese citizenship and 11.6% for pregnant women having Senegalese partners and 15.3% for Nigerian women and 14.5% for those having Nigerian partners. For the 45.5% of the vaccinated women (1233/2712), it was not possible to retrieve information about partners' citizenship (p < 0.05).

Vaccines **2021**, 9, 955 6 of 10

_			
Vaccination Adhesion in Pregnant Women			
Citizenship	Mothers% (n/N)	Fathers% (n/N)	
Italy	51.1 (3592/7034)	49.4 (2611/5288)	
Albany	26.5 (164/619)	26.3 (137/519)	
Romania	24.0 (85/354)	21.6 (42/194)	
China	36.0 (201/559)	36.2 (170/470)	
Morocco	10.4 (27/259)	14.0 (29/207)	
Peru	25.4 (36/141)	20.8 (11/53)	
Nigeria	15.3 (13/85)	14.5 (9/62)	
Senegal	13.5 (11/88)	11.6 (8/69)	
N.D.	-	45.5 (1233/2712)	
Other	21.5 (199/924)	15.0 (78/489)	

Table 2. Tdap vaccination adhesion in pregnant women by mothers' and fathers' citizenship.

3.2. Tdap Vaccination Adhesion Analysis by Parents' Educational and Occupational Status

We then retrieved information about mothers' marital status and both parents' educational profiles. Not married women had the highest Tdap vaccination rate (46.8%), followed by those married (40.2%); the separated and the divorced vaccinated women were 27.7% and 37.7%, respectively; for almost 42% of them, this information was not detected. Moreover, none of the widowed women were vaccinated (0/4). The chi-squared test applied to mothers' marital status was statistically significant (p < 0.05). Looking at the educational background, it appears that the vaccination adhesion trend would go hand in hand with mothers' academic qualifications: 55.0% of women who held a first-level degree (bachelor's degree) were vaccinated, 50.8% of those holding a second-level degree (master's degree), 42.1% of women holding a high school certificate, and finally, 33.1% of vaccinated women had a middle school qualification; for 38% of the vaccinated women, this information was not detected. The lowest vaccination rate was represented by women who did not hold any scholastic qualification (14.1%) (p < 0.05). Tdap vaccination adhesion rates of pregnant women are comparable when considering the fathers' academic qualification: the majority of them (51.6%) had a partner with a master's degree, 44.8% had a partner with a high school certificate, 44.4% had a partner with a bachelor's degree, 36.3% had a partner with a middle school certificate, and lastly, 13.4% of vaccinated women had a partner with no qualifications. For almost half of the vaccinated pregnant women (44.8%), information about their partners' qualifications was not available (p < 0.05). Furthermore, employed mothers reflected a high rate of Tdap vaccinated women (49.6%) compared to those unemployed (35.5%). The chi-squared analysis gave a statistically significant outcome (p < 0.05).

3.3. Analysis of Previous Pregnant Status, Deliveries and Voluntary Termination of Pregnancy (VTP)

Only a small percentage of women who had previously conceived had received Tdap vaccination (almost 37%) in 2019, while 52.3% among those expecting their first child were vaccinated. More than half of the women who were delivering for the first time received a Tdap dose (51.9%). The percentage of vaccinated women decreased by the number of previous deliveries: 39.5% (one delivery), 31.9% (two deliveries) and 26.4% (three or more deliveries) (Figure 2). Tdap vaccination adhesion in those who had previously aborted spontaneously is 43% (the lowest rate at 26.3% for \geq 4 abortions); on the other hand, the Tdap vaccination trend in those who aborted with a voluntary termination of pregnancy (VTP) decreases overall by the number of VTPs. The Chi-squared test was highly statistically significant for VTPs and the number of previous deliveries (p < 0.01 and p < 0.001, respectively). However, it was not significant for the number of previous abortions.

Vaccines **2021**, 9, 955 7 of 10




Figure 2. Percentage distribution of Tdap vaccinated women by number of previous deliveries, abortions and VTPs.

Only the 5% of women in our sample (506/10063) were medically assisted to begin the pregnancy, and 56.5% of them got a Tdap vaccine dose, whereas 43.5% of them were unvaccinated. We also considered the number of medical visits during pregnancy and, those women who had up to four visits showed an average vaccination rate of 24.9% (compared to the overall 43.0%); whereas women who had a number of visits between 5 and \geq 13 during their pregnancy showed a vaccination rate of 43.9% (p < 0.05).

3.4. Comparison of Tdap Vaccination Adhesion in 2019 and 2020

We also retrieved Tdap vaccination adhesion for the year 2020. We found an overall slightly increased trend rising from 43% in 2019 to 47.3% in 2020. Florence and Empoli were the geographical areas that registered the greatest Tdap vaccination increase in these two years: from 42.9% to 47.5% and 33.4% to 45.7%, respectively. The area of Prato was confirmed to be the top one, with 51.4% of vaccinated women (50.8% in 2019). Overall, women appeared to be more vaccinated in the year 2020 compared to 2019 for the following socio-demographic characteristics, with a comparable pattern for each analyzed parameter: parents' citizenship (p < 0.0001), mothers' marital status (p < 0.0001), fathers' educational level (p < 0.0001), mothers' professional occupation (p < 0.05), medically assisted procreation (p < 0.05) and the number of visits during pregnancy (p < 0.0001).

4. Discussion

Despite the excellent pertussis VC at 24 months (>95% both in Italy and Tuscany region), a few cases of whooping cough in infants still occur [8,16]. The most effective way to keep protecting the newborns from pertussis is to vaccinate pregnant women with a dose of Tdap in their third trimester of pregnancy to ensure antibody protection to the baby. The aim of this study was to describe the socio-demographic characteristics and determinants of Tdap vaccination of pregnant women in the LHU-TC during the year 2019 and compare the vaccination adhesion to the year 2020. Our sample population enrolled 10,063 pregnant women in 2019, and this well represented the number of newborns in the area of Pistoia (1831), Prato (1752) and the area of Florence (5136) and Empoli (1545), giving a total number of 10,264 babies [17]. Women between 35–39 years of age showed a higher vaccination percentage (48% in 2019 and 52.4% in 2020) than those younger (i.e., 22.7% 18–24 years old in 2019 and 26.1% in 2020). According to the NIP 2017–2019, the best time for Tdap vaccination during pregnancy is from the 27th to the 36th week of gestation [10]. Despite these recommendations, however, the Tdap VC among pregnant

Vaccines 2021, 9, 955 8 of 10

women remains very low not only in Italy but also worldwide [18,19]. In Southern Italy, the Tdap vaccine adhesion in pregnant women is about 1.7% [20], in the Abruzzo region between 1.2%-15% (for both influenza and Tdap or only one of them) [21], whereas in countries, such as Belgium, it reached the 64% [22,23]. The main reason for women's refusal appears to be the lack of appropriate information provided by the GP and obstetricians and/or gynecologists [24]. Unaware or poorly aware pregnant women were more likely to feel that the recommended vaccines administered during pregnancy (Tdap and influenza) were very dangerous for them and for their unborn child [25-27]. The cultural and demographic background also represents a great variable in the access to vaccination. Indeed, Moroccan, Senegalese and Nigerian mothers showed the lowest level of Tdap vaccination amongst those enrolled in our study, and the same results were observed when considering the father's citizenship. Since the 1980s, only a few pertussis cases have been reported in Morocco [28] and Senegal [29]; however, Nigeria seemed to be having a great number of cases in the last 40 years, peaking at 92.266 pertussis cases in the year 1985 [30]. Mothers' academic level, as well as employment type, increased the vaccination awareness and adhesion greatly, as is also widely reported in the literature [31,32]. Having a high educational background might facilitate a pregnant woman's communication with physicians and greater accessibility to different sources and ability to understand and interpret the received information. The year of the SARS-CoV-2 outbreak registered an increase of Tdap vaccination adhesion in pregnant women, rising from 43.0% in 2019 to 47.3% in 2020. The pandemic has indeed increased women's perceptions and fears about childbirth [33,34]. Thus, women may have chosen to be immunized against preventable infectious diseases to feel safer for themselves and their child.

5. Conclusions

Our study shows for the first time the level of Tdap immunization in pregnant women within the Florence area (Italy). This screenshot highlights how, although the several promotion campaigns adopted in the territory, pregnant women appear not to be fully aware of the vaccination's beneficial effect both for themselves and for their babies. The lack of information provided by physicians and healthcare staff seems to be the main reason why women expecting a child refuse to get the vaccination, being worried about the safety of vaccines. Thus, since the Tdap vaccination is the only preventive available tool to immunize newborns, it is strongly necessary to improve the training of the healthcare workers (gynecologists, midwives, pediatricians, GPs, healthcare workers, health assistants and medical doctors) to ensure a high and efficient level of information is provided to future mothers. Moreover, pertussis prevention in infanthood is based not only on the mothers' immunization programs but also on keeping the VC rates high (95%) in all age groups. It is therefore important to administer Tdap booster doses in adults every ten years. The goal is to reduce significantly the circulation of Bordetella pertussis within the population. Finally, this study could be used as a baseline information tool to design future successful vaccination strategies targeted to pregnant women.

Author Contributions: Conceptualization, D.B., G.M. and M.G.S.; methodology, D.B.; software, D.B.; validation, D.B. and B.B.; formal analysis, D.B. and B.B.; investigation, D.B. and B.B.; resources, B.B.; data curation, B.B.; writing—original draft preparation, B.B. and A.B.; writing—review and editing, B.B., D.B., A.B. and S.B.; visualization, B.B.; supervision, A.B., P.B. and S.B.; project administration, LHU- TC. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Annual data collection of childbirth assistance certificates (CedAP) is an institutional activity carried out at LHU level throughout the country. Our data were routinary collected at the LHU of Central Tuscany and they were analyzed in aggregated way and anonymously. The authors didn't collect any additional information and they did not have direct contact with pregnant women. So, it was not necessary to submit any official protocol to the Ethics

Vaccines **2021**, 9, 955 9 of 10

Committee. Anyway, all activities performed were conducted according to the guidelines of the Declaration of Helsinki.

Informed Consent Statement: Annual data collection of childbirth assistance certificates (CedAP) is an institutional activity carried out at LHU level throughout the country and it was not necessary to collect informed consent from pregnant women.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy reasons of LHU policies.

Acknowledgments: The authors would like to thank all the health care workers of the LHU-TC for their help in the realization of the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. WHO. Global Advisory Committee on Vaccine Safety. Safety of Immunization during Pregnancy. A Review of the Evidence Available online: https://www.who.int/publications/i/item/safety-immunization-pregnancy (accessed on 1 July 2021).
- Leuridan E.E.; Nunes M.C.; Jones C.E. Maternal Immunization. Acad. Press 2020 Elsevier Inc. DOI: https://doi.org/10.1016/C2016-0-05288-9. Available online: https://www.sciencedirect.com/book/9780128145821/maternal-immunization (accessed on 01 July 2021)
- 3. ECDC Pertussis: Annual Epidemiological report for 2018 Available online: https://www.ecdc.europa.eu/sites/default/files/doc-uments/AER_for_2018_pertussis.pdf (accessed on 01 July 2021).
- 4. WHO. Pertussis Vaccine-Preventable Diseases Available online: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO SurveillanceVaccinePreventable 16 Pertussis R1.pdf?ua=1 (accessed on 1 July 2021).
- 5. The History of Vaccines. An educational resource by the College of Physicians of Philadelphia. Available online: https://www.historyofvaccines.org/timeline/all (accessed on 1 July 2021).
- 6. Lichty, J.A.; Slavin, B.; Bradford, W.L. An Attempt to Increase Resistance to Pertussis in Newborn Infants By Immunizing Their Mothers During Pregnancy. *J. Clin. Invest.* **1938**, *17*, 613–621, doi:10.1172/jci100987.
- 7. Fiasca, F.; Gabutti, G.; Mattei, A. Trends in hospital admissions for pertussis infection: A nationwide retrospective observational study in italy, 2002–2016. *Int. J. Environ. Res. Public Health* **2019**, *16*, 1–11, doi:10.3390/ijerph16224531.
- 8. ARS Toscana. La sorveglianza epidemiologica delle malattie infettive in Toscana. Rapporto Novembre 2019. Available online: https://www.ars.toscana.it/images/pubblicazioni/Rapporti/2019/Rapporto_malattie_infettive.pdf (accessed on 20 May 2021).
- 9. Wiley, K.E.; Zuo, Y.; Macartney, K.K.; McIntyre, P.B. Sources of pertussis infection in young infants: A review of key evidence informing targeting of the cocoon strategy. *Vaccine* **2013**, *31*, 618–625, doi:10.1016/j.vaccine.2012.11.052.
- 10. Ministry of Health. National Immunization Plan 2017-2019. Available online: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf (accessed on 1 July 2021).
- 11. Ministry of Health. Circular n. 0034074, 21/11/2018. Vaccinazioni raccomandate per le donne in età fertile e in gravidanza. ER-RATA CORRIGE. Italy. Available online: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2018&cod-Leg=66751&parte=1 &serie=null (accessed on 30 June 2021).
- Ministry of Health. Circular n. 33045, 12/11/2019. Vaccinazioni raccomandate per le donne in età fertile e in gravidanza. Aggiornamento Novembre 2019. Italy. Available online: https://www.trovanorme. salute.gov.it/norme/render-NormsanPdf?anno=2019&codLeg=71540&parte=1%20&serie=null (accessed on 1 July 2021).
- 13. CDC. Pregnancy and Whooping Cough Available online: https://www.cdc.gov/pertussis/pregnant/mom/get-vaccinated.html#:~:text=Vaccination during pregnancy offers the best protection&text=Getting a Tdap vaccine between,months old by 78%251 (accessed on 20 June 2021).
- 14. Tuscany Region-Vaccinazioni di Soggetti a Rischio. Available online: https://www.regione.toscana.it/-/vaccinazioni-per-ledonne-in-eta-fertile-gravidanza-e-post-partum (accessed on 20 May 2021).
- 15. Tuscany Region. Libretto di Gravidanza. Available online: https://www.regione.toscana.it/documents/10180/16188197/libretto+di+gravidanza.pdf/11a12951-619e-4a8a-a6f1-65501868e749 (accessed on 20 May 2021).
- 16. Epicentro: Le Vaccinazioni in Italia. Available online: https://www.epicentro.iss.it/vaccini/dati_Ita#pertosse (accessed o 20 May 2021).
- 17. Istat. Bilancio Demografico Anno 2019. Available online: http://demo.istat.it/bil/index.php?anno=2019&lingua=ita (accessed on 21 May 2021).
- 18. Razzaghi, H.; Kahn, K.E.; Black, C.L.; Lindley, M.C.; Jatlaoui, T.C.; Fiebelkorn, A.P.; Havers, F.P.; D'Angelo, D.V.; Cheung, A.; Ruther, N.A.; et al. Influenza and Tdap Vaccination Coverage Among Pregnant Women—United States, April 2020. MMWR. *Morb. Mortal. Wkly. Rep.* **2020**, *69*, 1391–1397, doi:10.15585/mmwr.mm6939a2.
- Kharbanda, E.O.; Vazquez-Benitez, G.; Lipkind, H.S.; Klein, N.P.; Cheetham, T.C.; Naleway, A.L.; Lee, G.M.; Hambidge, S.; Jackson, M.L.; Omer, S.B.; McCarthy, N. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. *Vaccine* 2016, 10, 968–973.

Vaccines 2021, 9, 955 10 of 10

Agricola, E.; Gesualdo, F.; Alimenti, L.; Pandolfi, E.; Carloni, E.; D'Ambrosio, A.; Russo, L.; Campagna, I.; Ferretti, B.; Tozzi, A.E. Knowledge attitude and practice toward pertussis vaccination during pregnancy among pregnant and postpartum Italian women. *Hum. Vaccines Immunother.* 2016, 12, 1982–1988, doi:10.1080/21645515.2016.1188242.

- 21. Scatigna, M.; Appetiti, A.; Pasanisi, M.; D'Eugenio, S.; Fabiani, L.; Giuliani, A.R. Experience and attitudes on vaccinations recommended during pregnancy: Survey on an Italian sample of women and consultant gynecologists. *Hum. Vaccin Immunother.* **2021**, *6*, 1–8, doi:10.1080/21645515.2021.1894061. Epub ahead of print. PMID: 33956557.
- 22. Martens, K.; Cabore, R.N.; Huygen, K.; Hens, N.; Van Damme, P.; Leuridan, E. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. *Vaccine* **2016**, *34*, 142–150, doi:10.1016/j.vaccine.2015.10.098.
- 23. Laenen, J.; Roelants, M.; Devlieger, R.; Vandermeulen, C. Influenza and pertussis vaccination coverage in pregnant women. *Vaccine* **2015**, *33*, 2125–2131, doi:10.1016/j.vaccine.2015.03.020.
- 24. Barchitta, M.; Maugeri, A.; Magnano, R.; Lio, S.; Clara, M.; Rosa, L.; Mastra, C. La; Favara, G.; Giunta, G.; Cianci, A.; et al. Vaccination Status of Mothers and Children from the 'Mamma & Bambino' Cohort. *Vaccine* **2021**, *9*, 1–11, doi:org/10.3390/vaccines9020168.
- 25. Krishnaswamy, S.; Cheng, A.C.; Wallace, E.M.; Buttery, J.; Giles, M.L. Understanding the barriers to uptake of antenatal vaccination by women from culturally and linguistically diverse backgrounds: A cross-sectional study. *Hum. Vaccines Immunother.* **2018**, *14*, 1591–1598, doi:10.1080/21645515.2018.1445455.
- 26. D'Alessandro, A.; Napolitano, F.; D'Ambrosio, A.; Angelillo, I.F. Vaccination knowledge and acceptability among pregnant women in Italy. *Hum. Vaccines Immunother.* **2018**, *14*, 1573–1579, doi:10.1080/21645515.2018.1483809.
- Marchetti, F., Vilca LM, Cetin, I. Insights and expectations for Tdap vaccination of pregnant women in Italy. *J. Matern. Fetal. Neonatal. Med.* 2021, 34, 2132–2139, doi:10.1080/14767058.2019.1659240. Epub 2019 Sep 4. PMID: 31456459.
- 28. WHO Vaccine-Preventable Diseases: Monitoring System. 2019 Global Summary Morocco Available online: https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=MAR (accessed on 26 August 2021)
- WHO Vaccine-Preventable Diseases: Monitoring System. 2019 Global Summary Senegal Available online: https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=SEN#(accessed on 26 August 2021)
- 30. WHO Vaccine-Preventable Diseases: Monitoring System. 2019 Global Summary Nigeria Available online: https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=NGA (accessed on 26 August 2021)
- 31. Lu, P.; O'Halloran, A.; Kennedy, E.D.; Williams, W.W.; Kim, D.; Parker Fiebelkorn, A.; Donahue, S.; Bridges, C.B. Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015. *Vaccine* 2017, 35, 3104–3115, doi:10.1016/j.vaccine.2017.04.028.Awareness.
- 32. Dudley, M.Z.; Limaye, R.J.; Salmon, D.A.; Omer, S.B.; O'Leary, S.T.; Ellingson, M.K.; Spina, C.I.; Brewer, S.E.; Bednarczyk, R.A.; Malik, F.; et al. Racial/Ethnic Disparities in Maternal Vaccine Knowledge, Attitudes, and Intentions. *Public Health Rep.* **2021**, 003335492097466, doi:10.1177/0033354920974660.
- 33. Ravaldi, C.; Wilson, A.; Ricca, V.; Homer, C.; Vannacci, A. Pregnant women voice their concerns and birth expectations during the COVID-19 pandemic in Italy. *Women Birth* **2021**, *34*, 335–343, doi:10.1016/j.wombi.2020.07.002.
- 34. Salehi, L.; Rahimzadeh, M.; Molaei, E.; Zaheri, H.; Esmaelzadeh-Saeieh, S. The relationship among fear and anxiety of COVID-19, pregnancy experience, and mental health disorder in pregnant women: A structural equation model. *Brain Behav.* **2020**, *10*, 1–8, doi:10.1002/brb3.1835.